Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
This could relate to different pharmacokinetic profiles, lower peak drug levels, or differences in how the oral versus injectable forms interact with the nervous system
Eli Lilly and Novo Nordisk now offer savings programs that can significantly reduce out-of-pocket costs, even for patients without insurance
As demand surges, companies are racing to develop new oral formulations of these medications, which are presently available only as injections
Itd also be nice to maybe see the company conduct or sponsor studies on the actual product some day
Wegovy costs around $1,350 per month, and Ozempic and Rybelsus are about $998, though savings programs may make this more affordable